These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Diabetes Secondary to Treatment with Statins. Laakso M; Kuusisto J Curr Diab Rep; 2017 Feb; 17(2):10. PubMed ID: 28155189 [TBL] [Abstract][Full Text] [Related]
10. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061 [TBL] [Abstract][Full Text] [Related]
11. Alirocumab as add-on therapy to statins: current evidence and clinical potential. Auer J; Berent R Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 in cholesterol metabolism: from bench to bedside. Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529 [TBL] [Abstract][Full Text] [Related]
13. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
15. Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. Filippatos TD; Panagiotopoulou T; Tzavella E; Elisaf MS J Cardiovasc Pharmacol Ther; 2018 May; 23(3):187-191. PubMed ID: 29409336 [TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
17. PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk. Brandts J; Müller-Wieland D Curr Atheroscler Rep; 2019 Jul; 21(10):40. PubMed ID: 31350672 [TBL] [Abstract][Full Text] [Related]
18. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
19. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Kruit JK; Kremer PH; Dai L; Tang R; Ruddle P; de Haan W; Brunham LR; Verchere CB; Hayden MR Diabetologia; 2010 Jun; 53(6):1110-9. PubMed ID: 20229095 [TBL] [Abstract][Full Text] [Related]
20. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]